『Breakpoints』のカバーアート

Breakpoints

Breakpoints

著者： Society of Infectious Diseases Pharmacists
無料で聴く

【Amazonプライム会員限定】今ならプレミアムプランが4か月 月額99円。

10月19日まで。※適用条件あり
The SIDP PodcastCopyright 2019 科学 衛生・健康的な生活
エピソード
  • #142 – Does oseltamivir harm critically ill patients? The REMAP-CAP results

    #142 – Does oseltamivir harm critically ill patients? The REMAP-CAP results
    2026/09/20

    Does oseltamivir harm critically ill patients with influenza? In this Breakpoints and Communicable collaboration, Erin McCreary and Josh Davis are joined by Steve Webb and Steve Tong to discuss the REMAP-CAP trial results that are challenging a long-standing intensive care practice. Together, they review the study design, key findings, and implications for clinical care, while highlighting the importance of randomized clinical trials in shaping evidence-based medicine. At the time of recording, the REMAP-CAP results were available as a preprint.

    Resources:

    · REMAP-CAP: A Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia, https://www.remapcap.org/

    References:

    1. Murthy S, et al. Oseltamivir for Critically Ill Patients with Influenza: A Randomised Trial. Lancet 2026. Preprint http://dx.doi.org/10.2139/ssrn.7172531

    Learn more about the Society of Infectious Diseases Pharmacists: https://protect2.fireeye.com/v1/url?k=4063f96c-1ff8c1be-4063b7ad-867b1e11f55a-4ebd02e8eaa2fcc2\&q=1\&e=caf63b63-0143-4fa9-a81b-8d3031af3116\&u=https%3A%2F%2Fsidp.org%2FAboutSIDP – About

    Instagram: @SIDPharm ( https://www.instagram.com/sidpharm/) or @breakpointspodcast_sidp (https://www.instagram.com/breakpointspodcast_sidp/) https://www.instagram.com/breakpointspodcast_sidp/?hl=en

    Facebook: https://www.facebook.com/sidprx

    LinkedIn: https://www.linkedin.com/company/sidp/https://www.linkedin.com/company/sidp/

    X: SIDP (@SIDPharm) / X

    SIDP welcomes pharmacists and non-pharmacist members with an interest in infectious diseases, learn how to join here: https://sidp.org/Become-a-Member

    Find out more at https://sidp.pinecast.co
    続きを読む 一部表示
    1 時間 3 分
  • #141 – Prostatitis: Hard to Reach, Harder to Treat

    #141 – Prostatitis: Hard to Reach, Harder to Treat
    2026/09/11

    Dr. Prathit Kulkarni, lead author of a recent state-of-the-art review on acute and chronic bacterial prostatitis, joins host Dr. Erin McCreary to discuss this complex disease state. They walk through diagnosis, epidemiology, treatment, and more. You won’t want to miss this episode!

    References:

    1. Kulkarni PA, Cortés-Penfield NW, Brehm TJ, et al. State-of-the-Art Review: Diagnosis and Management of Acute and Chronic Bacterial Prostatitis. Clin Infect Dis. 2026;82(1):1-13. doi:10.1093/cid/ciaf483

    Learn more about the Society of Infectious Diseases Pharmacists: SIDP - About

    Instagram: @SIDPharm ( https://www.instagram.com/sidpharm/) or @breakpointspodcast_sidp (https://www.instagram.com/breakpointspodcast_sidp/) https://www.instagram.com/breakpointspodcast_sidp/?hl=en

    Facebook: https://www.facebook.com/sidprx

    LinkedIn: https://www.linkedin.com/company/sidp/

    X: SIDP (@SIDPharm) / X

    SIDP welcomes pharmacists and non-pharmacist members with an interest in infectious diseases, learn how to join here: https://sidp.org/Become-a-Member
    続きを読む 一部表示
    59 分
  • #140 – Beta-lactamase inhibitors: “Scientifically elegant, just complex"

    #140 – Beta-lactamase inhibitors: “Scientifically elegant, just complex"
    2026/08/21
    Gram-negative resistance is beautifully intricate, scientifically elegant, and very complex. Nothing is more exciting than the recently approved and bursting pipeline of beta-lactamase inhibitors. Listen to Drs. Sam Aitken and Christophe Le Terrier, along with host Dr. Erin McCreary, describe the nuanced enzymology and other antibacterial properties of beta-lactamase inhibitors. This episode also discusses the concepts of stand-alone inhibitors, resistance development, and more. If you want to learn more about sulbactam, clavulanic acid, tazobactam, avibactam, relebactam, vaborbactam, durlobactam, enmetazobactam, zidebactam, nacubactam, ledaborbactam, taniborbactam, and xeruborbactam – this episode is for you! Funding for this podcast was provided by Shionogi Inc. References: 1. Le Terrier C, Nordmann P, Buchs C, et al. Wide dissemination of Gram-negative bacteria producing the taniborbactam-resistant NDM-9 variant: a One Health concern. J Antimicrob Chemother. 2023;78(9):2382-2384. doi:10.1093/jac/dkad210 2. Le Terrier C, Nordmann P, Buchs C, Poirel L. Effect of modification of penicillin-binding protein 3 on susceptibility to ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam, cefepime-taniborbactam, and cefiderocol of Escherichia coli strains producing broad-spectrum β-lactamases. Antimicrob Agents Chemother. 2024;68(4):e0154823. doi:10.1128/AAC.01548-23 3. Le Terrier C, Freire S, Viguier C, Findlay J, Nordmann P, Poirel L. Relative inhibitory activities of the broad-spectrum β-lactamase inhibitor xeruborbactam in comparison with taniborbactam against metallo-β-lactamases produced in Escherichia coli and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2024;68(6):e0157023. doi:10.1128/AAC.01570-23 4. Le Terrier C, Mlynarcik P, Sadek M, Nordmann P, Poirel L. Relative inhibitory activities of newly developed diazabicyclooctanes, boronic acid derivatives, and penicillin-based sulfone β-lactamase inhibitors against broad-spectrum AmpC β-lactamases. Antimicrob Agents Chemother. 2024;68(11):e0077524. doi:10.1128/AAC.00775-24 Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Instagram: @SIDPharm ( https://www.instagram.com/sidpharm/) or @breakpointspodcast_sidp (https://www.instagram.com/breakpointspodcast_sidp/) https://www.instagram.com/breakpointspodcast_sidp/?hl=en Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/ SIDP welcomes pharmacists and non-pharmacist members with an interest in infectious diseases, learn how to join here: https://sidp.org/Become-a-Member Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Stitcher, Google Play, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/https://sidp.pinecast.co/
    続きを読む 一部表示
    1 時間 16 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません